Accordingly, the administration of Igsu in BPH decreased the expression of PCNA and cyclin D1, which are major markers of cell proliferation, and it significantly increased the ratio of Bax/Bcl-2, which is a major marker of apoptosis compared to the untreated group. Here, BCL2 is linked to benign prostatic hyperplasia.